EGFR and non-small cell lung carcinoma: WBRT addition to EGFR-TKIs (gefitinib, erlotinib, and icotinib) have significantly increased survival for brain metastatic NSCLC patients with unknown EGFR status or without molecular selection (61, 64, 65, 71–73).